Iterum Therapeutics plc announced a new Medicare Part D rebate agreement that will place its oral penem antibiotic ORLYNVAH on the formularies of all three top U.S. pharmacy‑benefit managers. The deal is expected to cover more than 3.5 million lives and to take effect as early as the first quarter of 2026, expanding payer coverage and increasing the drug’s revenue potential.
The company also received U.S. Patent 12,544,337 for a bilayer tablet formulation of ORLYNVAH. The patent, which is Orange‑Book listable, will expire in December 2039 and will bring the total number of ORLYNVAH patents listed in the FDA’s Orange Book to five, reinforcing the company’s intellectual‑property portfolio and supporting future pricing and market exclusivity.
The rebate agreement follows prior agreements with the other two top Medicare Part D PBMs, positioning ORLYNVAH for broader formulary inclusion and patient access. Management highlighted that the coverage of more than 3.5 million lives is a significant milestone that could accelerate sales growth, especially as the drug was launched in August 2025 and is projected to generate 2026 net sales of $5 million to $15 million.
The U.S. patent adds a layer of protection that can help maintain pricing power amid a competitive market for uncomplicated urinary tract infection treatments. It also aligns with the company’s strategy to secure a robust IP moat while addressing the growing need for new oral antibiotics in the face of rising resistance.
The FDA has requested additional evidence from a supplemental new drug application to support a step‑down therapy indication for complicated urinary tract infections. The agency’s feedback indicates that further clinical data will be required before the indication can be approved, underscoring the regulatory path ahead for expanding ORLYNVAH’s therapeutic use.
Financially, Iterum has faced significant challenges, including a high debt burden and Nasdaq listing compliance issues. These developments in market access and IP protection are therefore critical for strengthening the company’s commercial position and improving its long‑term financial outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.